28 December 2017 | News
To expand synthetic biology product portfolio
GenScript is the world leader in gene synthesis, and a peptide, protein, and antibody research partner for fundamental life science research, translational biomedical research, early stage biopharmaceutical development and synthetic biology.
The company announced that it will undergo acquisition agreement with it and GenScript USA Holding Inc., its wholly owned subsidiary, has entered into an agreement to acquire 100 percent of the issued shares of CustomArray Inc.
CustomArray Inc.is a privately held DNA microarray company that provides customized oligonucleotide pools and microarrays to many of the world's leading academic and industrial organizations for applications in targeted sequencing, complex DNA libraries, synthetic biology, shRNA libraries, and CRISPR, from all of its shareholders.
CustomArray uses semiconductor chip technology to electrochemically synthesize DNA right on the chip surface.
The patented and proprietary technology allows the creation of large numbers of different oligonucleotides in a highly parallel, high-throughput, high-density, and cost-effective manner.
CustomArray, as a market leader in oligonucleotide pools, with one of the world's leading array-based synthesis technologies, strengthens GenScript's leadership in synthetic biology, such as gene synthesis, CRISPR library, shRNA library, enzyme and antibody engineering.
According to Brooke Anderson,CEO of CustomArray, GenScript's innovation, entrepreneurial spirit, and aggressive growth, along with its depth of marketplace knowledge and reach will make a highly desirable partner for his company.